8 of 113 works · Shared service.
An open initiative for scientific research reproducibility. Companion executable source code repositories pair a published paper with the code, data, and documentation needed to reproduce it, turning static publications into living evidence.
The companion shared service we run when Revenue Engineering is too early. The outcome it owns is proven demand: a named audience, a claim that survives contact with them, and a first step they will actually take.
A governed evaluation platform for hospitals and health systems. Instead of a procurement queue full of unranked vendor claims, a health system gets structured evaluation: who has been vetted, on what evidence, against which internal need.
Finds reimbursed demand in healthcare and states it in the terms a business plan needs: the claims-defined cohort, the counties where the gap is largest, the CMS signal that proves it, the CPT and HCPCS codes and bundles that pay for it, and the revenue at stake. It is a shared service to every other venture and the intelligence spine of Fund II.
A healthcare growth and care-access capability that turns fragmented patient demand into timely, scheduled care. The team designs, launches, and operates AI-driven demand intelligence, orchestration, and routing on behalf of provider organizations, filling real provider capacity instead of reporting clicks and leads. The portfolio's ventures draw on it as the shared demand-and-access engine.
An execution layer that turns the Microsoft 365 or Google Workspace a provider already pays for into a working digital front door. The argument is that most organizations do not need to buy more healthcare software; they need the software they own to actually run the work. It serves the portfolio as the shared front-door capability.
The shared revenue capability every company in the portfolio draws on. We define an outcome, build an AI Workforce™ that owns it end to end, and run it on one platform with the same observability and reporting for every firm.
A continuous clinical research infrastructure platform that reads signals across consented health transaction data for earlier detection and continuous research. Payshent is its funding and consent layer; Symvion is the intelligence layer that turns compensated patient data into detectable signal.
A family of USPTO filings around one invention, granted or pending, with its real status.
An operating company chartered by Studios, with an entity, an operator, and a closure path.
A capability built for the whole portfolio and designed to be spun out on its own.
A company funded, built, or spun out. (Lapsed filings remain in the patent register.)
A pool of capital with a written thesis and a stated deployment model.
Long-form publishing that makes the case for an invention or an operating model.
Standing research programs and publication series, including peer-reviewed work.
A landscape read that changed a filing or funding decision.
A defensive publication that puts prior art in the open so a bad patent cannot be filed later.
A structured intelligence asset that decides where capital, filings, or ventures go next.
A reusable operating method that the rest of the portfolio is built on.
A piece the founder published on his own site, tagged by type, that argues a finding in the open before it becomes a filing or a fund.
An owned online publication that makes the case for our work to a standing audience.